What did @dr.okeefe actually say?
Dr. O'Keefe, who identifies as board-certified in gastroenterology and weight loss, ran through the most common GLP-1 side effects: nausea, vomiting, constipation, diarrhea, and reflux. The practical advice was brief but specific. For nausea and vomiting, "we'll do a deep assessment of what it is that you're eating and try to focus on smaller portion sizes." For constipation, the fix is increasing fiber intake. The video closes with a reasonable disclaimer: "make sure you talk to your doctor if you're getting prescribed any of these GLP-1 or GLP-1 and GIP medications."
This is a short-form explainer, not a clinical consultation. The creator is speaking generally to a broad audience and isn't prescribing anything specific, which matters for how you evaluate the claims. The content is largely advice-adjacent rather than diagnostic, and that framing is appropriate for TikTok.
Does the science back this up?
Yes, mostly. The side effect profile described here matches what clinical trials and post-market surveillance have consistently shown. The STEP 1 trial (Wilding et al., 2021, NEJM) reported nausea in 44% of semaglutide participants, vomiting in 24.5%, diarrhea in 30%, and constipation in 24%. These are not rare events. They are the dominant reason patients discontinue GLP-1 therapy early.
The dietary interventions mentioned, smaller portions and increased fiber, also have mechanistic support. GLP-1 receptor agonists slow gastric emptying significantly (Nauck et al., 2004, Diabetologia), which is the primary driver of nausea and early satiety. Eating smaller meals reduces the volume load on a stomach that is already emptying slowly. As for fiber, a 2023 review in Obesity Reviews (Perakakis et al.) noted that constipation during GLP-1 therapy is partly motility-related, and fiber combined with adequate hydration is a reasonable first-line intervention, though the evidence base for fiber specifically in GLP-1-induced constipation is still thin.
What did they get wrong (or right)?
Mostly right, with one real gap. The creator mentions that "there are other things that can happen much more rare" but doesn't name any of them. That vagueness is a missed opportunity, and in some contexts, it matters. Pancreatitis is a labeled warning for GLP-1 medications. It is rare, but it is not trivial. The FDA label for semaglutide includes a warning about acute pancreatitis, and patients should know to stop the medication and seek care if they develop severe abdominal pain.
Similarly, the risk of gastroparesis-like symptoms, distinct from the typical nausea, has been flagged in case reports and a 2023 pharmacovigilance study (Sodhi et al., JAMA) that found higher rates of gastroparesis diagnoses in GLP-1 users compared to bupropion-naltrexone users. Gastric motility is the creator's specialty, so mentioning this would have added real value. Skipping the specific rare risks in favor of a vague "talk to your doctor" is technically fine, but a board-certified gastroenterologist could do better here.
What should you actually know?
The side effects described are real, common, and manageable for most people, but not everyone. Roughly 5 to 10 percent of participants in major trials discontinued due to GI adverse events (Davies et al., 2021, Lancet). Dose titration matters enormously. Both semaglutide and tirzepatide are started at low doses and increased slowly precisely to reduce GI burden, and many patients who get nausea at higher doses do fine if titration is slowed down.
The fiber advice for constipation is reasonable but incomplete without mentioning hydration. Fiber without adequate water intake can actually worsen constipation. For reflux specifically, which the creator listed but didn't address with a management strategy, there is growing evidence that GLP-1-associated delayed gastric emptying can worsen GERD symptoms and even pose aspiration risks in surgical settings (the American Society of Anesthesiologists issued guidance on this in 2023). If you have pre-existing reflux and are starting a GLP-1, that conversation with your prescriber is not optional.
- Nausea affects roughly 44% of semaglutide users in clinical trials and usually peaks in the first few weeks.
- Eating smaller, lower-fat meals before dosing can reduce nausea severity.
- Constipation from GLP-1 therapy is tied to slower gut motility, and fiber plus fluids is the standard first step.
- Rare but serious risks include pancreatitis and significant gastroparesis-like symptoms, both worth knowing before you start.
- If side effects are severe or persistent, slowing dose titration is an option, not a failure.